Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MME | P08473 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | XIAP | P98170 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13592564 | 1.00 | KMT2A (0.59) | KMT2AMMEALDH1A1MEN1MAPT | |
| SCHEMBL1790982 | 1.00 | KMT2A (0.59) | KMT2AMMEALDH1A1MEN1MAPT | |
| Trifluoroacetic Acid SCHEMBL10425462 | 0.91 | ALDH1A1 (0.53) | KMT2AMMEALDH1A1MEN1MAPT | |
| SCHEMBL10382329 | 0.91 | BACE1 (0.64) | KMT2AALDH1A1MEN1MMP8BACE1 | |
| SCHEMBL1751593 | 0.91 | BACE1 (0.64) | KMT2AALDH1A1MEN1MMP8BACE1 | |
| SCHEMBL12261267 | 0.91 | BACE1 (0.64) | KMT2AALDH1A1MEN1MMP8BACE1 | |
| SCHEMBL15623826 | 0.88 | ERCC1 (0.47) | KMT2AALDH1A1 | |
| SCHEMBL900959 | 0.88 | KMT2A (0.58) | KMT2AMMEALDH1A1MEN1MAPT | |
| SCHEMBL900956 | 0.88 | KMT2A (0.58) | KMT2AMMEALDH1A1MEN1MAPT | |
| SCHEMBL24050019 | 0.88 | BACE1 (0.59) | KMT2AMMEALDH1A1SLC1A2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150322094-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-11-12 | — | — | US | claimed |
| EP-2892343-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | Bayer CropScience AG (DE) | 2015-07-15 | — | — | EP | claimed |
| WO-2014037349-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-03-13 | — | — | WO | claimed |
| US-20150322094-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-11-12 | — | — | US | disclosed |
| WO-2008135488-A1 | ASPARTYL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008119773-A1 | AMIDE DERIVATIVES AS INHIBITORS OF ASPARTYL PROTEASES | MEDIVIR AB (SE) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119772-A1 | AMIDE DERIVATIVES AS INHIBITORS OF ASPARTYL PROTEASES | MEDIVIR AB (SE) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008107365-A1 | NEW COMPOUNDS | MEDIVIR AB (SE) | 2008-09-12 | — | — | WO | disclosed |
| US-7132568-B2 | Aspartyl protease inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-7115652-B2 | Aspartyl protease inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1644322-A1 | ASPARTYL PROTEASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1515944-A1 | ASPARTYL PROTEASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-2005005374-A1 | ASPARTYL PROTEASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20040147454-A1 | Aspartyl protease inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20040132782-A1 | Aspartyl protease inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2003106405-A1 | ASPARTYL PROTEASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322094-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | CAT, HSF1, HPD | KMT2A 3258/4885MME 4210/4885ALDH1A1 24/4885 |
| US-20040147454-A1 | Aspartyl protease inhibitors | BACE1, APP, BACE2 | KMT2A 3006/4885MME 28/4885ALDH1A1 2014/4885 |
| US-20040132782-A1 | Aspartyl protease inhibitors | BACE1, APP, BACE2 | KMT2A 3344/4885MME 32/4885ALDH1A1 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.